Many episodes of CIS are mild and resolve without treatment. In other cases, treatment with high dose oral or intravenous methylprednisolone (a steroid) is typically recommended.
An MS disease-modifying therapy is often recommended for people diagnosed with a CIS that is considered more likely to progress to clinically-definitely multiple sclerosis (CDMS), with the goal of delaying a second attack.
To learn about four large-scale clinical trials that have been conducted to determine whether early treatment following a CIS can delay the second clinical event, and therefore the diagnosis of clinically definite MS click on the following link:
Treatments for CIS